{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-087493","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-08-11T11:30:34+00:00","discovered_at":"2026-08-11T11:35:00.262574+00:00","generated_at":"2026-08-11T11:35:27.275059+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Incannex receives final A$5.1M R&D tax refund; 2026 non-dilutive capital tops A$11.2M","bullets":["Received final A$5,102,788.30 refund under Australian R&D Tax Incentive Program on Aug 11, 2026.","Combined with prior A$6,039,162.43, total 2026 non-dilutive proceeds exceed A$11.2 million.","Refund follows approval of overseas findings and amendment of FY25 income tax return.","Funds strengthen debt-free balance sheet; support clinical assets IHL-42X and PSX-001.","Company expects additional R&D tax incentive funding in 2027 for eligible activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-087493","json":"https://secwatch.observer/filing/0001213900-26-087493.json","markdown":"https://secwatch.observer/filing/0001213900-26-087493.md","text":"https://secwatch.observer/filing/0001213900-26-087493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026087493/0001213900-26-087493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026087493/ea0301333-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:35:27.275059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}